Matthew Shields Biography and Net Worth

Matthew (Matt) Shields was appointed Executive Vice President, Teva Global Operations (TGO) in June 2024.

Matt leads one of the largest and most fully integrated manufacturing and supply networks in the pharmaceutical industry. Each day, TGO colleagues are committed to a common goal, delivering a reliable supply of high-quality innovative medicines, affordable generics and biopharmaceuticals to millions of patients.

With more than 25 years of experience serving in various senior management roles in the global pharmaceutical industry, Matt brings to Teva a passion for improving the lives of patients by enabling a purpose-driven culture focused on operational excellence.

Matt has significant experience at every stage of the manufacturing and supply process. Prior to joining Teva, he served as Senior Vice President, for Manufacturing at Merck Animal Health (known as MSD Animal Health outside of the United States and Canada), where he oversaw end-to-end manufacturing, supply chain, procurement, and process development. Prior to Merck Animal Health, he served in various operations leadership roles for Sanofi and Amgen, Inc.

Matt holds an undergraduate degree in Chemical Engineering & Materials Science Engineering from the University of Connecticut and an MBA from Bryant University in Rhode Island.

What is Matthew Shields' net worth?: The estimated net worth of Matthew Shields is at least $283.59 thousand as of June 3rd, 2025. Shields owns 9,989 shares of Teva Pharmaceutical Industries stock worth more than $283,588 as of December 5th. This net worth approximation does not reflect any other investments that Shields may own. Learn More about Matthew Shields' net worth.
How old is Matthew Shields?: Shields is currently 50 years old. There are 5 older executives and no younger executives at Teva Pharmaceutical Industries. The oldest executive at Teva Pharmaceutical Industries is Mr. David R. Mcavoy J.D., Executive VP & Chief Legal Officer, who is 61 years old. Learn More on Matthew Shields' age.
How do I contact Matthew Shields?: The corporate mailing address for Shields and other Teva Pharmaceutical Industries executives is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. Teva Pharmaceutical Industries can also be reached via phone at (723) 914-8213 and via email at [email protected]. Learn More on Matthew Shields' contact information.
Has Matthew Shields been buying or selling shares of Teva Pharmaceutical Industries?: Matthew Shields has not been actively trading shares of Teva Pharmaceutical Industries in the last ninety days. Most recently, Matthew Shields sold 6,206 shares of the business's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a transaction totalling $105,626.12. Following the completion of the sale, the executive vice president now directly owns 9,989 shares of the company's stock, valued at $170,012.78. Learn More on Matthew Shields' trading history.
Who are Teva Pharmaceutical Industries' active insiders?: Teva Pharmaceutical Industries' insider roster includes Vikki Conway (Acting Head of Global Human Resources), Rosemary Crane (Director), Richard Daniell (VP), Sven Dethlefs (EVP), Eric Drape (VP), Christine Fox (EVP, U.S. Commercial), Richard Francis (President, CEO & Director), Hafrun Fridriksdottir (VP), Eric Hughes (insider), Placid Jover (Insider), Eliyahu Kalif (CFO), Roberto Mignone (Director), Mark Sabag (Insider), Eli Shani (EVP), Matthew Shields (EVP), David Stark (VP), and Amir Weiss (CAO). Learn More on Teva Pharmaceutical Industries' active insiders.
Are insiders buying or selling shares of Teva Pharmaceutical Industries?: During the last twelve months, insiders at the sold shares 5 times. They sold a total of 551,001 shares worth more than $12,113,818.32. The most recent insider tranaction occured on November, 6th when Director Roberto Mignone sold 200,000 shares worth more than $4,822,000.00. Insiders at Teva Pharmaceutical Industries own 0.5% of the company. Learn More about insider trades at Teva Pharmaceutical Industries.
Information on this page was last updated on 11/6/2025.

Matthew Shields Insider Trading History at Teva Pharmaceutical Industries

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/3/2025	Sell	6,206	$17.02	$105,626.12	9,989

Matthew Shields Buying and Selling Activity at Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Company Overview

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Today's Range

Now: $28.39

$27.96

$28.46

50 Day Range

MA: $22.28

$18.30

$28.39

2 Week Range

Now: $28.39

$12.47

$28.46

Volume

11,018,001 shs

Average Volume

11,645,990 shs

Market Capitalization

$32.56 billion

P/E Ratio

47.32

Dividend Yield

N/A

Beta

0.67

Matthew Shields Biography and Net Worth

What is Matthew Shields' net worth?

How old is Matthew Shields?

How do I contact Matthew Shields?

Has Matthew Shields been buying or selling shares of Teva Pharmaceutical Industries?

Who are Teva Pharmaceutical Industries' active insiders?

Are insiders buying or selling shares of Teva Pharmaceutical Industries?